gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2022-32-5-43-50gastro-j-675Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESПрогностические модели первичного склерозирующего холангитаPrognostic Models of Primary Sclerosing Cholangitishttps://orcid.org/0000-0003-2569-1699ДолгушинаА. И.DolgushinaA. I.

Долгушина Анастасия Ильинична — доктор медицинских наук, доцент, заведующая кафедрой госпитальной терапии 

454092, г. Челябинск, ул. Воровского, д. 64

Anastasia I. Dolgushina — Dr. Sci. (Med.), Associate Professor, Head of the Department of Hospital Therapy

454092, Chelyabinsk, Vorovskogo str., 64

dolgushinaai@yandex.ruhttps://orcid.org/0000-0002-3481-8092СелянинаА. А.SelyaninaA. A.

Селянина Анна Алексеевна — ассистент кафедры госпитальной терапии

454092, г. Челябинск, ул. Воровского, д. 64

Anna A. Selyanina — Assistant of the Department of Hospital Therapy

454092, Chelyabinsk, Vorovskogo str., 64

anna-selyanina@mail.ruhttps://orcid.org/0000-0002-0824-7214ДубровинаВ. В.DubrovinaV. V.

Дубровина Виктория Вячеславовна — студентка 6-го курса

454092, г. Челябинск, ул. Воровского, д. 64

Viktoria V. Dubrovina — 6th year student

454092, Chelyabinsk, Vorovskogo str., 64

vikki_1997.97@mail.ruhttps://orcid.org/0000-0002-7385-8505ИсянгильдинаГ. А.IsyangildinaG. A.

Исянгильдина Гульназ Амировна — студентка 6-го курса

454092, г. Челябинск, ул. Воровского, д. 64

Gulnaz A. Isyangildina — 6th year student

454092, Chelyabinsk, Vorovskogo str., 64

isangildinagulnaz31@gmail.comhttps://orcid.org/0000-0002-7385-8505ОлевскаяЕ. Р.OlevskayaE. R.

Олевская Елена Рафаиловна — доктор медицинских наук, доцент, заведующая отделением эндоскопии

454092, г. Челябинск, ул. Воровского, д. 64

454048, г. Челябинск, ул. Воровского, д. 70

Elena R. Olevskaya — Dr. Sci. (Med.), Associate Professor, Head of the Department of Endoscopy

454092, Chelyabinsk, Vorovskogo str., 64

endo74@mail.ruФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииSouth Ural State Medical UniversityФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; ГБУЗ «Челябинская областная клиническая больница»South Ural State Medical University; Chelyabinsk Regional Clinical Hospital2022120120233254350Copyright © Долгушина А.И., Селянина А.А., Дубровина В.В., Исянгильдина Г.А., Олевская Е.Р., 20232023Долгушина А.И., Селянина А.А., Дубровина В.В., Исянгильдина Г.А., Олевская Е.Р.Dolgushina A.I., Selyanina A.A., Dubrovina V.V., Isyangildina G.A., Olevskaya E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/675Цель исследования

Цель исследования: Изучить значимость прогностических шкал на когорте пациентов с первичным склерозирующим холангитом, проживающих в Челябинской области.

Материалы и методы

Материалы и методы. В исследование включен 21 пациент с подтвержденным диагнозом первичного склерозирующего холангита (ПСХ) и длительностью заболевания не менее двух лет. Исследуемой первичной конечной точкой являлся летальный исход. На основании данных медицинских карт производили расчет шкалы MELD, Mayo Risk Score, Amsterdam-Oxford PSC Score, PREsTo score и UK-PSC Score. Статистическая обработка проводилась при помощи программы SPSS Statistics v.22.

Результаты

Результаты. Ретроспективная оценка риска летальности по шкале MELD, Mayo Risk Score и Amsterdam- Oxford PSC Score не выявила статистически значимой разницы между умершими и выжившими пациентами.

Наибольшую прогностическую ценность показала шкала UK-PSC Score (р = 0,046).

Заключение

Заключение. Новая прогностическая модель UK-PSC Score показала преимущества в прогнозировании летального исхода у пациентов ПСХ по сравнению с другими шкалами.

Aim

Aim: to study the significance of prognostic scales in a target group of patients with primary sclerosing cholangitis (PSC) living in the Chelyabinsk region.

Materials and methods

Materials and methods. The study included 21 patients with a confirmed diagnosis of primary sclerosing cholangitis (PSC) and a disease duration of at least two years. The primary endpoint studied was death. The MELD, Mayo Risk Score, Amsterdam-Oxford PSC Score, PREsTo score, and UK-PSC Score scales were calculated based on the medical records. Statistical processing was carried out using the SPSS Statistics v.22 application.

Results

Results. A retrospective assessment of the risk of mortality using the MELD, Mayo Risk Score and Amsterdam-

Oxford PSC Score did not reveal a statistically significant difference between deceased and surviving patients. The UK-PSC Score scale showed the highest predictive value (p = 0.046).

Conclusion

Conclusion. The new predictive model UK-PSC Score showed advantages in predicting death in PSC patients compared to other scales.

первичный склерозирующий холангитновые прогностические моделипрогнозвыживаемостьцирроз печениprimary sclerosing cholangitisnew prognostic modelsprognosissurvivalliver cirrhosisReferencesИвашкин В.Т., Широкова Е.Н., Маевская М.В., Павлов Ч.С., Шифрин О.С., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Рос журн гастроэнтерол гепатол колопроктол. 2015;25(2):41–57.Ivashkin V.T., Shirokova E.N., Maevskaya M.V., Pavlov Ch.S., Shifrin O.S., Maev I.V., et al. Clinical recommendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver on the diagnosis and treatment of cholestasis. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(2):41–57 (In Russ.).Chapman M.H., Thorburn D., Hirschfield G.M., Webster G.G.J., Rushbrook S.M., Alexander G., et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356–78. DOI: 10.1136/gutjnl-2018-317993Chapman M.H., Thorburn D., Hirschfield G.M., Webster G.G.J., Rushbrook S.M., Alexander G., et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356–78. DOI: 10.1136/gutjnl-2018-317993Lindor K.D., Kowdley K.V., Harrison M.E. American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646–59. DOI: 10.1038/ajg.2015.112Lindor K.D., Kowdley K.V., Harrison M.E. American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646–59. DOI: 10.1038/ajg.2015.112Ji S.G., Juran B.D., Mucha S., Folseraas T., Jostins L., Melum E., et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269–73. DOI: 10.1038/ng.3745Ji S.G., Juran B.D., Mucha S., Folseraas T., Jostins L., Melum E., et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269–73. DOI: 10.1038/ng.3745Karlsen T.H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis — a comprehensive review. J Hepatol. 2017;67(6):1298–323. DOI: 10.1016/j.jhep.2017.07.022Karlsen T.H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis — a comprehensive review. J Hepatol. 2017;67(6):1298–323. DOI: 10.1016/j.jhep.2017.07.022Molodecky N.A., Kareemi H., Parab R., Barkema H.W., Quan H., Myers R.P., Kaplan G.G. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9. DOI: 10.1002/hep.24247Molodecky N.A., Kareemi H., Parab R., Barkema H.W., Quan H., Myers R.P., Kaplan G.G. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9. DOI: 10.1002/hep.24247Boonstra, K., Weersma, R.K., van Erpecum, K.J., Rauws, E.A., Spanier, B.W.M., Poen, A.C., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55. DOI: 10.1002/hep.26565Boonstra, K., Weersma, R.K., van Erpecum, K.J., Rauws, E.A., Spanier, B.W.M., Poen, A.C., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55. DOI: 10.1002/hep.26565Vladut C., Ciocirlan M., Bilous D., ?andru V., Stan-Ilie M., Panic N., et al. An Overview on Primary Sclerosing Cholangitis. Journal of Clinical Medicine. 2020;9(3):754. DOI: 10.3390/jcm9030754Vladut C., Ciocirlan M., Bilous D., ?andru V., Stan-Ilie M., Panic N., et al. An Overview on Primary Sclerosing Cholangitis. Journal of Clinical Medicine. 2020;9(3):754. DOI: 10.3390/jcm9030754Пазенко Е.В., Райхельсон К.Л., Кондрашина Э.А., Габрусская Т.В., Герасимова О.А. Особенности течения первичного склерозирующего холангита, сочетающегося с воспалительными заболеваниями кишечника. ЭиКГ. 2017;10(146): 33–39.Pazenko E.V., Raykhelson K.L., Kondrashina E.A., Gabrusskaya T.V., Gerasimova O.A. Features of the course of primary sclerosing cholangitis, combined with inflammatory bowel diseases. EiCG. 2017;10(146): 33–39 (In Russ.).Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7. DOI: 10.1016/s0168-8278(01)00288-4Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7. DOI: 10.1016/s0168-8278(01)00288-4Tischendorf J.J., Hecker H., Kruger M., Manns M.P., Meier P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007;102(1):107–14. DOI: 10.1111/j.1572-0241.2006.00872.xTischendorf J.J., Hecker H., Kruger M., Manns M.P., Meier P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007;102(1):107–14. DOI: 10.1111/j.1572-0241.2006.00872.xWeismuller T.J., Trivedi P.J., Bergquist A., Imam M., Lenzen H., Ponsioen C.Y., et al. International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8):1975–84.e8. DOI: 10.1053/j.gastro.2017.02.038Weismuller T.J., Trivedi P.J., Bergquist A., Imam M., Lenzen H., Ponsioen C.Y., et al. International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8):1975–84.e8. DOI: 10.1053/j.gastro.2017.02.038Trivedi P.J., Crothers H., Mytton J., Bosch S., Iqbal T., Ferguson J., Hirschfield G.M. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020;159(3):915–28. DOI: 10.1053/j.gastro.2020.05.049Trivedi P.J., Crothers H., Mytton J., Bosch S., Iqbal T., Ferguson J., Hirschfield G.M. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020;159(3):915–28. DOI: 10.1053/j.gastro.2020.05.049European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022Al Mamari S., Djordjevic J., Halliday J.S., Chapman R.W. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34. DOI: 10.1016/j.jhep.2012.10.013Al Mamari S., Djordjevic J., Halliday J.S., Chapman R.W. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34. DOI: 10.1016/j.jhep.2012.10.013Lindström L., Hultcrantz R., Boberg K.M., Friis-Liby I., Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841–6. DOI: 10.1016/j.cgh.2012.12.032Lindström L., Hultcrantz R., Boberg K.M., Friis-Liby I., Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841–6. DOI: 10.1016/j.cgh.2012.12.032Goode E.C., Clark A.B., Mells G.F., Srivastava B., Spiess K., Gelson W.T.H., et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology. 2019;69(5):2120–35. DOI: 10.1002/hep.30479Goode E.C., Clark A.B., Mells G.F., Srivastava B., Spiess K., Gelson W.T.H., et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology. 2019;69(5):2120–35. DOI: 10.1002/hep.30479Rupp C., Bode K.A., Leopold Y., Sauer P., Gotthardt D.N. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4):1380–9. DOI: 10.1016/j.bbadis.2017.09.012Rupp C., Bode K.A., Leopold Y., Sauer P., Gotthardt D.N. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4):1380–9. DOI: 10.1016/j.bbadis.2017.09.012Jendrek S.T., Gotthardt D., Nitzsche T., Widmann L., Korf T., Michaels M.A., et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66(1):137–44. DOI: 10.1136/gutjnl-2016-311739Jendrek S.T., Gotthardt D., Nitzsche T., Widmann L., Korf T., Michaels M.A., et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66(1):137–44. DOI: 10.1136/gutjnl-2016-311739Vesterhus M., Holm A., Hov J.R., Nygard S., Schrumpf E., Melum E., et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol. 2017;66(6):1214–22. DOI: 10.1016/j.jhep.2017.01.019Vesterhus M., Holm A., Hov J.R., Nygard S., Schrumpf E., Melum E., et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol. 2017;66(6):1214–22. DOI: 10.1016/j.jhep.2017.01.019Trivedi P.J., Tickle J., Vesterhus M.N., Eddowes P.J., Bruns T., Vainio J., et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67(6):1135–45. DOI: 10.1136/gutjnl-2016-312354Trivedi P.J., Tickle J., Vesterhus M.N., Eddowes P.J., Bruns T., Vainio J., et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67(6):1135–45. DOI: 10.1136/gutjnl-2016-312354Ehlken H., Wroblewski R., Corpechot C., Arrive L., Lezius S., Hartl J., et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut. 2016;65(7):1230–2. DOI: 10.1136/gutjnl-2016-311452Ehlken H., Wroblewski R., Corpechot C., Arrive L., Lezius S., Hartl J., et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut. 2016;65(7):1230–2. DOI: 10.1136/gutjnl-2016-311452Bjornsson E., Lindqvist-Ottosson J., Asztely M., Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):502–8. DOI: 10.1111/j.1572-0241.2004.04106.xBjornsson E., Lindqvist-Ottosson J., Asztely M., Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):502–8. DOI: 10.1111/j.1572-0241.2004.04106.xPetrovic B.D., Nikolaidis P., Hammond N.A., Martin J.A., Petrovic P.V., Desai P.M., Miller F.H. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci. 2007;52(12):3499–506. DOI: 10.1007/s10620-006-9720-1Petrovic B.D., Nikolaidis P., Hammond N.A., Martin J.A., Petrovic P.V., Desai P.M., Miller F.H. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci. 2007;52(12):3499–506. DOI: 10.1007/s10620-006-9720-1Шептулина А.Ф., Широкова Е.Н., Ивашкин В.Т. Неинвазивные методы диагностики фиброза печени у больных первичным билиарным циррозом и первичным склерозирующим холангитом: роль непрямых сывороточных маркеров. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):52–63. DOI: 10.22416/1382-4376-2016-26-3-52-63Sheptulina A.F., Shirokova Y.N., Ivashkin V.T. Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):52–63 (In Russ.). DOI: 10.22416/1382-4376-2016-26-3-52-63de Vries E.M., de Krijger M., Färkkilä M., Arola J., Schirmacher P., Gotthardt D., et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology. 2017;65(3):907–19. DOI: 10.1002/hep.28963de Vries E.M., de Krijger M., Färkkilä M., Arola J., Schirmacher P., Gotthardt D., et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology. 2017;65(3):907–19. DOI: 10.1002/hep.28963Eaton J.E., Dzyubak B., Venkatesh S.K., Smyrk T.C., Gores G.J., Ehman R.L., et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016;31(6):1184–90. DOI: 10.1111/jgh.13263Eaton J.E., Dzyubak B., Venkatesh S.K., Smyrk T.C., Gores G.J., Ehman R.L., et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016;31(6):1184–90. DOI: 10.1111/jgh.13263Schmeltzer P.A., Russo M.W. Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis. J Clin Med. 2021;28(19):4476. DOI: 10.3390/jcm10194476Schmeltzer P.A., Russo M.W. Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis. J Clin Med. 2021;28(19):4476. DOI: 10.3390/jcm10194476Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–94. DOI: 10.4065/75.7.688Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–94. DOI: 10.4065/75.7.688Goet J.C., Floreani A., Verhelst X., Cazzagon N., Perini L., Lammers W.J., et al. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol. 2019;71(5):992–9. DOI: 10.1016/j.jhep.2019.06.012Goet J.C., Floreani A., Verhelst X., Cazzagon N., Perini L., Lammers W.J., et al. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol. 2019;71(5):992–9. DOI: 10.1016/j.jhep.2019.06.012Vesterhus M., Hov J.R., Holm A., Schrumpf E., Nygard S., Godang K., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015;62(1):188–97. DOI: 10.1002/hep.27825Vesterhus M., Hov J.R., Holm A., Schrumpf E., Nygard S., Godang K., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015;62(1):188–97. DOI: 10.1002/hep.27825Saffioti F., Roccarina D., Vesterhus M., Hov J.R., Rosenberg W., Pinzani M., et al. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. Eur J Clin Invest. 2019;49(5):e13088. DOI: 10.1111/eci.13088Saffioti F., Roccarina D., Vesterhus M., Hov J.R., Rosenberg W., Pinzani M., et al. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. Eur J Clin Invest. 2019;49(5):e13088. DOI: 10.1111/eci.13088Eaton J.E., Vesterhus M., McCauley B.M., Atkinson E.J., Schlicht E.M., Juran B.D., et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology. 2020;71:214–24. DOI: 10.1002/hep.30085Eaton J.E., Vesterhus M., McCauley B.M., Atkinson E.J., Schlicht E.M., Juran B.D., et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology. 2020;71:214–24. DOI: 10.1002/hep.30085

The authors declare that there are no conflicts of interest present.